Evidence map›Paper›PMID 36341430›Full record

ArticleFrontiers in immunology2022

Feasibility of avian antibodies as prophylaxis against enterotoxigenic escherichia coli colonization.

Kyle Brumfield, Hyesuk Seo, Nnebuefe Idegwu, Chad Artman, Laura Gonyar, James Nataro, Weiping Zhang, David Sack, James Geyer, Julius Goepp

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Kyle BrumfieldMaryland Pathogen Research Institute, University of Maryland, College Park, MD, United States.
Hyesuk SeoDepartment of Pathobiology, University of Illinois Urbana-Champaign, Urbana, IL, United States.
Nnebuefe IdegwuDepartment of Therapeutics Development, Scaled Microbiomics, Hagerstown, MD, United States.
Chad ArtmanDepartment of Therapeutics Development, Scaled Microbiomics, Hagerstown, MD, United States.
Laura GonyarDepartment of Pediatrics, University of Virginia, Charlottesville, VA, United States.
James NataroDepartment of Pediatrics, University of Virginia, Charlottesville, VA, United States.
Weiping ZhangDepartment of Pathobiology, University of Illinois Urbana-Champaign, Urbana, IL, United States.
David SackBloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States.
James GeyerInstitute for Rural Health Research, University of Alabama, Tuscaloosa, AL, United States.
Julius GoeppDepartment of Therapeutics Development, Scaled Microbiomics, Hagerstown, MD, United States.
University of Illinois Urbana-Champaign · USUniversity of Virginia · USJohns Hopkins University · USUniversity of Alabama · USUniversity of Maryland, College Park · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This research aims to evaluate the feasibility of using avian immunoglobulins (IgY) raised against adhesion factors of enterotoxigenic Methods: IgY samples were prepared from eggs of hens immunized with an adhesin-tip multiepitope fusion antigen (MEFA), developed against nine adhesin tip epitopes derived from clinically relevant ETEC strains. The resulting IgY was evaluated for its ability to inhibit adhesion of ETEC to cell-surface targets. Potential impacts of anti-MEFA IgY on growth of both pathogenic and commensal Results: Enzyme linked immunosorbent assay (ELISA) titers were achieved for IgY targeting each of the nine individual epitopes included in the adhesin-tip MEFA. Furthermore, anti-MEFA titers exceeding 1:2 Conclusions: These findings demonstrate that IgY targeting ETEC adhesin-tip MEFA have the potential to disrupt

Indexed as

Enterotoxigenic Escherichia coliEscherichia coli InfectionsAdhesins, BacterialAnimalsAntibodies, BacterialAntigens, BacterialChickensDiarrheaEpitopesFeasibility StudiesFemaleHumansMammalsAdhesins, BacterialAntibodies, BacterialAntigens, BacterialEpitopesavian immunoglobulinsenterotoxigenic E. coli (ETEC)IgYpolyclonal antibodies (PAbs)prophylaxistravelers diarrhea

Identifiers

PMID36341430
PMCPMC9627289
OpenAlexW4306843348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.